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was 49 years (range, 21–71 years). Ten patients underwent a sibling
transplantation (5 standard regimen, 5 reduced intensity), and 11
underwent an unrelated transplantation (5 standard regimen, 6
reduced intensity); graft T-cell depletion was done in 15 patients
(Campath-1H in 7, OKT3 in 8). Neutropenia was observed in 5
patients, resolving in all of them. VGC was discontinued tempo-
rarily in these 5 patients until they recovered from neutropenia.
Four of them received concomitant mycophenolate mofetil. No
adverse effects were otherwise reported. The median follow-up
after transplantation is 12 months. Six patients died during the
study, from disease progression (2 patients), fungal infection (1
patient), or GVHD (3 patients). None of the 21 patients experi-
enced CMV reactivation or disease while on VGC. Conclusions:
These early results suggest that VGC has a role in the posttrans-
plantation setting, and that further evaluation of VGC in CMV
prophylaxis or preemptive therapy is needed.
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ACTUALIZING A WELLNESS PROGRAM AND WELLNESS ROOM IN THE
ONCOLOGY SETTING: GETTING A PROGRAM THROUGH A LARGE IN-
STITUTION
Galgay, L., Swift, S., Cusack, G., Jones-Wells, A., Rivera, P.,
Chisholm, L. The National Institutes of Health, Bethesda, MD.
The Clinical Center (CC) of the National Institutes of Health
(NIH) is a hospital solely dedicated to conducting biomedical
research. Participation in the rigors of a phase I or II clinical trial
requires inner strength, support, and ability to follow through with
the demands of research. Nurses on the Oncology, Experimental
Transplantation Unit at the CC acknowledge the special needs of
their patients, caregivers, and staff, and strive to ﬁnd ways to lessen
the impact of these demands. A group of oncology nurses at the
CC formed a Complementary and Alternative Medicine (CAM)
Cancer Nursing Interest Group. A review of the literature reveals
that a focus on patients’ psychological, social, physical, and spiri-
tual needs promotes improved quality of life in oncology patients.
The CAM Interest Group recognized the importance of integra-
tive therapies as one strategy to assist patients in dealing with their
chronic illness. This presentation outlines the development and
inception of a wellness program to aid patients in dealing with
chronic illness using integrative therapies such as relaxation ther-
apy, guided imagery, and a “room for silence.”
The “plan-do-check-act” model serves as our conceptual model
for development and evaluation of the program. Benchmarking
with preeminent institutions nationwide, and identiﬁcation of key
stakeholders within the institution, as well as the National Cancer
Institute (NCI) and the National Center for Complementary and
Alternative Medicine (NCCAM), was instrumental in the develop-
ment of the program.
With visionary nursing leadership and extensive collaboration
with the CC interdisciplinary team, the program has been incor-
porated and follows the credentialing guidelines proposed by the
CC’s Integrative Medicine Taskforce. Self-care, empowerment,
healing versus curing, relaxation, and comfort are emphasized, and
an examination of theories and models is used for health education
and promotion. Dedicated space has been allocated for a “room for
silence,” which is designed for meditation, prayer, imagery, and
journaling. Patients and staff evaluate the wellness program on an
ongoing basis and changes are incorporated based on feedback.
Incorporating a wellness program fosters improved patient out-
comes, enhances quality of life for oncology patients, and serves as
a model for integrative care.
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URSODIOL-BASED PROPHYLAXIS FOR VENO-OCCLUSIVE DISEASE
(VOD): A RETROSPECTIVE RISK-BASED REVIEW OF OUTCOMES FOL-
LOWING ALLOGENEIC STEM CELL TRANSPLANTATION
Thompson, J.M., Akard, L.P., Dugan, M.J., English, K., Jansen, J.
Indiana Blood & Marrow Transplantation, Indianapolis, IN.
A total of 307 sequential patients allografted at our institution
over the past decade were evaluated retrospectively to study treat-
ment-related hepatotoxicity, and prevention thereof, following the
use of various ursodiol-based VOD prophylaxis regimens. The
patient group comprised 178 males and 129 females, median age 42
years. There were 227 related and 80 unrelated donors, 271
matched and 36 mismatched. Diagnoses included acute leukemia
in 129 patients (42%), chronic leukemia in 89 patients (29%),
lymphoma in 37 patients (12%), myelodysplasia in 21 patients
(7%), myeloma in 15 patients (5%), aplastic anemia in 10 patients
(3%), and other in 6 patients (2%). A total of 158 patients (51%)
received TBI, 112 patients (36%) received busulfan, and 37 pa-
tients (12%) received methotrexate. All patients whose bilirubin
exceeded 2.0 mg/dL postgrafting (166 patients; 54%) were evalu-
ated for cause. The mean day (D) of maximal bilirubin elevation for
this group was D19. Non-VOD causes included regimen-related
toxicity in 57 patients (34%), GVHD in 50 patients (30%), infec-
tion/sepsis/multiorgan dysfunction in 19 patients (12%), and
ABO-realted hemolysis in 18 patients (11%). The diagnosis of
VOD was made by criteria described previously. VOD accounted
for the cause of hyperbilirubinemia in 23 patients in this subset of
166 patients (14%). Of the total group of 307 patients, 164 patients
(53%) received VOD prophylaxis, 38 patients (23%) received oral
ursodiol (Urso) alone (600–900 mg/day), 69 patients (42%) re-
ceived IV Urso  heparin (Hep)(800 U/hr), 54 patients (33%)
received SQ Urso  Lovenox (Lov)(40 mg/day), and 3 patients
(2%) received Hep alone. Overall, 23 patients (7.5%) developed
VOD, with only 7 patients dying due to VOD (2.3%). The inci-
dence of VOD was not signiﬁcantly different for / Urso (7.5%
vs 7.6%), / Lov (7.4% vs 7.5%), / Hep (11.1% vs 6.4%;
P  .18); / Urso  Lov (7.4% vs 7.5%), and / Urso Hep
(7.2% vs 7.6%). Data were also analyzed for the effect of 7 known
risk factors for VOD: age  40 years, unrelated donor, preparative
regimen including busulfan or TBI, baseline AST, methotrexate
for GVHD prophylaxis, and history of liver disease. Risk factors (f)
for VOD occurred as follows: 0(f), 5 (2%); 1(f), 90 (29%); 2(f), 150
(49%); 3(f), 54 (17%); 4(f), 8 (3%). The occurrence of VOD (%)
correlated with the number of risk factors (f) pregrafting: 0(f), 0/5
(0%); 1(f), 5/90 (6%); 2(f), 10/150 (7%); 3(f), 7/54 (13%); 4(f), 1/8
(12%). The overall incidence of VOD, and related death, is lower
in this series than historical reports. The beneﬁt of ursodiol-based
prophylactic regimens appears to be greatest in patients with 2 or
fewer VOD-related risk factors.
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VORICONAZOLE (VOR) IS SAFE AND EFFECTIVE AS PROPHYLACTIC ANTI-
FUNGAL THERAPY FOR ALLOGENEIC STEM CELL TRANSPLANTATION (AT)
Martin, T.1, O’Malley, R.2, Working, M.2, Guglielmo, J.1,
Fischbach, N.1, Damon, L.1, Navarro, W.1, Kaplan, L.1, Linker, C.1
1University of California, San Francisco, San Francisco, CA; 2Wake
Forest Medical School, Winston Salem, NC.
Background: Despite ﬂuconazole (FLU) prophylaxis in AT,
invasive fungal infection (IFI) continues to cause signiﬁcant mor-
bidity and mortality. VOR is a second-generation triazole with
broad-spectrum activity. Since August 2002, VOR has been used as
antifungal prophylaxis at UCSF Medical Center. The goals of this
study were to evaluate the incidence of IFI up to d100 and assess
safety and organ toxicity (OT). Methods: The records of patients
receiving VOR prophylaxis from August 2002 to May 2004 were
reviewed. Demographics, conditioning, stem cell source, HLA
status, laboratory and radiology results, OT, and survival were
analyzed. All patients were hospitalized throughout AT. Tacroli-
mus and MTX / MMF were used for GVHD prophylaxis.
VOR (4 mg/kg twice a day IV/PO) was administered through day
100 post-AT. EORTC criteria were used to assess for IFI.
Results: A total of 72 patients were identiﬁed (44 males and 28
females, mean age 54 years [range, 19–70]). Of these, 41 patients
received low-intensity conditioning and 31 received myeloablative
therapy. PBSCs were used more frequently than BM (60 vs 12).
Sibling donors were used for 37 patients; unrelated donors, for 35
patients. The 100- and 180-day TRM rates were 8% and 13%.
The incidence of grade II-IV aGVHD was 16%. Two patients
(3%) developed deﬁnitive IFI (1 mucor and 1 aspergillus plus
scedosporium). No probable IFIs were identiﬁed. Both patients
with deﬁnitive IFI died, 1 from grade IV GVHD and 1 from
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